Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given.Cutaneous Toxicities from Anti-Cancer Therapies, by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy. This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.
1. Introduction - p. xii 2. Contents - p. xiv 3. Part I: Special Considerations - p. 1 4. 1. Reactions in Patients with Skin of Color - p. 3 5. 2. Reactions in Pediatric Patients - p. 8 6. Part II: Reaction Patterns - p. 9 7. 3. Morbilliform Reactions - p. 11 8. 4. Lichenoid Reactions - p. 14 9. 5. Psoriasiform Reactions - p. 17 10. 6. Acneiform Reactions - p. 22 11. 7. Intertriginous Reactions - p. 28 12. 8. Bullous Reactions - p. 33 13. 9. Panniculitis-Like Reactions - p. 38 14. 10. Purpuric Reactions - p. 42 15. 11. Erythroderma - p. 47 16. 12. Edematous Reactions - p. 50 17. 13. Sclerosing Reactions - p. 56 18. 14. Pigmentary Alterations - p. 60 19. 15. Reactions on the Hands and Feet - p. 67 20. 16. Oral Toxicities - p. 74 21. 17. Mucositis - p. 77 22. 18. Hair and Nail Abnormalities - p. 81 23. 19. Radiation Recall - p. 89 24. 20. Inflamed Actinic Keratoses - p. 92 25. 21. Severe Cutaneous Adverse Reactions - p. 95 26. Part III: Anticancer Agents and Classes - p. 105 27. Section I: Cytotoxic Chemotherapy - p. 107 28. 22. Alkylating Agents - p. 107 29. 23. Antimetabolites - p. 114 30. 24. Topoisomerase Inhibitors - p. 128 31. 25. Anthracyclines - p. 131 32. 26. Microtubule Inhibitors - p. 135 33. 27. Bleomycin - p. 141 34. Section II: Targeted Agents - p. 145 35. 28. Epidermal Growth Factor Receptor (EGFR) Inhibitors - p. 145 36. 29. BRAF Inhibitors - p. 153 37. 30. MEK Inhibitors - p. 159 38. 31. PI3-Kinase Inhibitors - p. 165 39. 32. mTOR Inhibitors - p. 170 40. 33. Multikinase Inhibitors - p. 175 41. 34. BTK Inhibitors - p. 179 42. 35. BCR/ABL/C-Kit Inhibitors - p. 186 43. 36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors - p. 192 44. 37. Proteasome Inhibitors - p. 197 45. 38. Hormonal Therapies - p. 200 46. 39. CCR4 Inhibitors - p. 205 47. Section III: Immunotherapy and Immune Modulators - p. 209 48. 40. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors - p. 209 49. 41. Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Inhibitors - p. 214 50. 42. Thalidomide and Lenalidomide - p. 226 51. Part IV: Other Anticancer Treatment–Associated Toxicities - p. 229 52. 43. Radiation Therapy - p. 231 53. 44. Pruritus - p. 235 54. Appendix - p. 245 55. Photo Credits - p. 251 56. Index - p. 253
No hay muestra disponible
No hay ficha técnica disponible
Many oncologic therapies used to treat cancer have significant implications for the skin. These dermatologic reactions follow recognizable patterns and are closely related to the type of treatment given.Cutaneous Toxicities from Anti-Cancer Therapies, by Drs. Allireza Alloo and Nicole LeBoeuf, provides comprehensive coverage of cutaneous toxicities caused by the full spectrum of oncologic modes of treatment—specifically cytotoxic chemotherapy, targeted chemotherapy, and immunotherapy. This portable photoguide is a quick bedside handbook for dermatologists, oncologists, primary care providers, emergency room physicians, and other health care professionals who see patients undergoing treatment for cancer.
1. Introduction - p. xii 2. Contents - p. xiv 3. Part I: Special Considerations - p. 1 4. 1. Reactions in Patients with Skin of Color - p. 3 5. 2. Reactions in Pediatric Patients - p. 8 6. Part II: Reaction Patterns - p. 9 7. 3. Morbilliform Reactions - p. 11 8. 4. Lichenoid Reactions - p. 14 9. 5. Psoriasiform Reactions - p. 17 10. 6. Acneiform Reactions - p. 22 11. 7. Intertriginous Reactions - p. 28 12. 8. Bullous Reactions - p. 33 13. 9. Panniculitis-Like Reactions - p. 38 14. 10. Purpuric Reactions - p. 42 15. 11. Erythroderma - p. 47 16. 12. Edematous Reactions - p. 50 17. 13. Sclerosing Reactions - p. 56 18. 14. Pigmentary Alterations - p. 60 19. 15. Reactions on the Hands and Feet - p. 67 20. 16. Oral Toxicities - p. 74 21. 17. Mucositis - p. 77 22. 18. Hair and Nail Abnormalities - p. 81 23. 19. Radiation Recall - p. 89 24. 20. Inflamed Actinic Keratoses - p. 92 25. 21. Severe Cutaneous Adverse Reactions - p. 95 26. Part III: Anticancer Agents and Classes - p. 105 27. Section I: Cytotoxic Chemotherapy - p. 107 28. 22. Alkylating Agents - p. 107 29. 23. Antimetabolites - p. 114 30. 24. Topoisomerase Inhibitors - p. 128 31. 25. Anthracyclines - p. 131 32. 26. Microtubule Inhibitors - p. 135 33. 27. Bleomycin - p. 141 34. Section II: Targeted Agents - p. 145 35. 28. Epidermal Growth Factor Receptor (EGFR) Inhibitors - p. 145 36. 29. BRAF Inhibitors - p. 153 37. 30. MEK Inhibitors - p. 159 38. 31. PI3-Kinase Inhibitors - p. 165 39. 32. mTOR Inhibitors - p. 170 40. 33. Multikinase Inhibitors - p. 175 41. 34. BTK Inhibitors - p. 179 42. 35. BCR/ABL/C-Kit Inhibitors - p. 186 43. 36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors - p. 192 44. 37. Proteasome Inhibitors - p. 197 45. 38. Hormonal Therapies - p. 200 46. 39. CCR4 Inhibitors - p. 205 47. Section III: Immunotherapy and Immune Modulators - p. 209 48. 40. Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Inhibitors - p. 209 49. 41. Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Inhibitors - p. 214 50. 42. Thalidomide and Lenalidomide - p. 226 51. Part IV: Other Anticancer Treatment–Associated Toxicities - p. 229 52. 43. Radiation Therapy - p. 231 53. 44. Pruritus - p. 235 54. Appendix - p. 245 55. Photo Credits - p. 251 56. Index - p. 253
No hay muestra disponible
No hay ficha técnica disponible
